Henry Schein (HSIC) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Henry Schein

NasdaqGS•Healthcare•Medical Distribution

$85.09+0.05(<0.01%)Market open

Market Cap

$9.69B

P/E

24.1x

P/S

0.7x

P/B

3.1x

Henry Schein, Inc. provides health care products and services to office-based dental and medical practitioners worldwide. It operates through Global Distribution and Value-Added Services; Global Specialty Products; and Global Technology segments. The Global Distribution and Value-Added Services segment distributes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, PPE products, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as provides equipment repair services, financial services on a non-recourse basis, continuing education services for practitioners, consulting, and other services. It also markets and sells a portfolio of consumable merchandise under its own corporate brand. The Global Specialty Products segment engage in manufacturing, marketing, and sales of dental implant and biomaterial products; and endodontic, orthodontic and orthopedic products, and other health care-related products and services. The Global Technology segment is involved in the development and distribution of practice management software, e-services, and other products which are distributed to health care providers. The company serves dental practices, laboratories, physician practices, and ambulatory surgery centers, as well as government, institutional health care clinics, home health providers, and other alternate care clinics. It has a strategic partnership with GoTu Technology to help dental practices address ongoing staffing challenges. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

How this company scores

GoodMetricSide Score: 63/100

Strongest: Cash & Earnings Quality (24/25); weakest: Profitability (9/25).

Profitability9/25

Growth17/25

Balance Sheet & Red Flags13/25

Cash & Earnings Quality24/25

Strengths

Rising free cash flowCash-backed earningsConsistent growthNo share dilution

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/E · 24.1x5y range 14.3x – 29.4x

Currently near its 20-quarter median.

P/S · 0.7x5y range 0.6x – 1.0x

Currently near its 20-quarter median.

P/B · 3.1x5y range 2.3x – 3.4x

Currently near its 20-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

Some Concerns

Leverage Risk

Watch

Debt-to-equity has risen 20.1% recently — increasing financial risk even if the current ratio is manageable.

Price & Volume

Market Cap $9.69B

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $13.60B
Q. Revenue: $3.46B
TTM EBITDA: $954.00M
TTM Op. Income: $680.00M
Q. Op. Income: $171.00M
TTM Net Income: $403.00M
Q. Net Income: $94.00M
EPS: $0.83
Shares Out.: $113.45M

$13.60B in TTM revenue grew 6.5% YoY, reaching $3.46B last quarter. TTM EBITDA of $954.00M and TTM operating income of $680.00M show growth is flowing through to the bottom line. TTM net income of $403.00M means revenue is converting into profit. Across the last 8 quarters, TTM revenue has risen for 5 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 31.8%
EBITDA Margin: 7.0%
Op. Margin: 4.9%
Net Margin: 2.7%

Op. margin of 4.9% is up 0.3% YoY — cost efficiency is improving. Net margin at 2.7% and gross margin of 31.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is up 6% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: 24.1x
P/S Ratio: 0.7x
P/B Ratio: 3.1x

At 24.1x P/E, the stock trades within typical market levels. P/S of 0.7x and P/B of 3.1x provide additional context. Use the growth and margin sections to judge whether the multiple is justified. Over the past year, P/E is up 5% — a weakening trend.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $11.38B
Cash: $157.00M
Long-Term Debt: $2.30B
Book Value: $3.16B
D/E Ratio: 0.7
Debt/EBITDA: 9.5

With $11.38B in assets and $2.30B in long-term debt, D/E is 0.7and book value is $3.16B — a conservative capital structure with a cushion to weather downturns. Across the last 8 quarters, debt/equity has risen for 6 consecutive quarters — a weakening trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $242.00M
TTM Free Cash Flow: $569.00M
FCF Margin: 4.2%
FCF / Net Income: 1.4

TTM FCF of $569.00M on $242.00M in operating cash flow. The FCF / Net Income ratio of 1.4x means free cash flow covers net income — earnings are backed by cash. Over the past year, free cash flow is up 50% — an improving trend.